TB activists for first time challenge TB drug patent in India

Médecins Sans Frontières (MSF) is supporting a patent challenge filed in India this week by two tuberculosis survivors, to prevent pharmaceutical corporation Johnson & Johnson (J&J) from extending its monopoly on the tuberculosis drug bedaquiline.

Tuberculosis

India

Latest news

Letter |

11 February 2019

Malaysia

Malaysia’s compulsory licence for sofosbuvir is a positive step for public health and innovation

Médecins Sans Frontières (MSF) Access Campaign wrote a letter of support to the Malaysian government commending the issuance of a government use licence to enable access to an affordable version of hepatitis C drug sofosbuvir. The licence issued by Malaysia on 20 September 2017 eliminated patent barriers and has resulted in the scale-up of treatment in public hospitals throughout the country.

Technical brief |

08 February 2019

India

Opposing patent application for bedaquiline formulation in India

Video |

08 February 2019

TB survivors challenge J&J's patent on TB drug in India

Phumeza and Nandita suffered permanent hearing loss because of toxic drugs used to treat their drug-resistant TB.

Now they’re working to ensure that this doesn’t happen to anyone else.

Statement |

31 January 2019

144th WHO EB: Follow-up to the high-level meetings of the United Nations General Assembly on health-related issues: Antimicrobial resistance

WHO Executive Board, 144th Session, January 2019
MSF Statement: Agenda item 5.8.1 (EB144/19) – Follow-up to the high-level meetings of the United Nations General Assembly on health-related issues: Antimicrobial resistance

Statement |

30 January 2019

144th WHO EB: Follow-up to the high-level meetings of the United Nations General Assembly on health-related issues: Ending tuberculosis

WHO Executive Board, 144th Session, January 2019
MSF Statement: Agenda item 5.8.3 (EB144/21) – Follow-up to the high-level meetings of the United Nations General Assembly on health-related issues: Ending tuberculosis

Statement |

29 January 2019

144th WHO EB: Medicines, vaccines and health products - Access to medicines and vaccines

WHO Executive Board, 144th Session, January 2019
MSF Statement: Agenda item 5.7.1 (EB144/17) – Medicines, vaccines and health products: Access to medicines and vaccines

Events |

29 January 2019

MSF statements at WHO Executive Board 144th session

MSF representatives are attending the 144^th session of the WHO executive board meetings and will be speaking on a number of topics.

Statement |

29 January 2019

144th WHO EB: Medicines, vaccines and health products: Cancer medicines

Feature story |

28 January 2019

Snakebite stories from Abdurafi, northern Ethiopia

Feature story |

27 January 2019

A long and painful journey

MSF helps patients in Ukraine navigate the difficulties of treatment for drug-resistant tuberculosis.

Feature story |

24 January 2019

Antibiotic resistance - Testimonies from Mosul

Video |

24 January 2019

Tackling multidrug resistance in Mosul

In April 2018, MSF opened a post-operative care hospital in this city, to provide services for people injured by violent or accidental trauma during the recent conflict. Soon after the activities started, data showed that more than one out of three patients were affected by antibiotic resistance. MSF had to adapt to the situation quickly and to build more isolation rooms in order to provide its patient with the adequate care and insure their recovery. Today, the hospital is one of the only structures in the country providing them with optimized antimicrobial therapy.